Home > Haematology > EHA 2019 > Lymphoid Malignancies > ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By
Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy
Conference
EHA 2019
Trial
Phase 3, ASCEND
Dr Paolo Ghia (Vita-Salute San Raffaele University, Italy) presented the findings from the phase 3 ASCEND study of the Bruton’s tyrosine kinase inhibitor (BTKi) acalabrutinib in relapsed or refractory chronic lymphocytic leukaemia (CLL). The study demonstrated that acalabrutinib had superior progression-free survival versus rituximab with idelalisib or bendamustine [1]. The ASCEND trial was a global, multicentre, open-label, phase 3 study that randomised 310 patients to receive either acalabrutinib monotherapy or the physician’s choice of either idelalisib plus rituximab or bendamustine. Acalabrutinib is a highly selective, potent inhibitor of BTK that has previously demonstrated substantial activity and improved tolerability in patients with CLL, similar to ibrutinib. In this study, acalabrutinib monotherapy significantly improved progression-free survival, with a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on